Navigation Links
Clinical Data Reinforce Safety and Efficacy of Boston Scientific's Two Drug- Eluting Stent Platforms
Date:3/29/2009

NATICK, Mass. and ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed three-year results from the SPIRIT II Clinical Trial and a pooled meta-analysis of two-year data from the SPIRIT II and III Trials. SPIRIT II and SPIRIT III are prospective, randomized, non-inferiority trials with 300 and 1,002 patients respectively, designed to compare the safety and efficacy of the PROMUS(R) (XIENCE V(TM)) Everolimus-Eluting Coronary Stent to Boston Scientific's first-generation TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent. SPIRIT II three-year results were presented by Patrick W. Serruys, M.D., Ph.D, and the two-year meta-analysis was presented by Yoshinobu Onuma, M.D., at the 58th Annual Scientific Session of the American College of Cardiology.

The two-year pooled meta-analysis was intended to estimate the incidence of low frequency events or outcomes in key subgroups, and included 892 patients randomized to the PROMUS (XIENCE V) Stent and 410 patients treated with the TAXUS Stent. While overall pooled results and some subgroups at two years favored the PROMUS (XIENCE V) Stent for rates of Major Adverse Cardiac Events (MACE), the MACE results in patients with diabetes favored the TAXUS Stent.

"Clinical data presented at ACC continue to reinforce the value of Boston Scientific's two-drug portfolio," said Keith D. Dawkins, M.D., Associate Chief Medical Officer of Boston Scientific. "While the PROMUS (XIENCE V) Stent performed well against the TAXUS Stent in the meta-analysis, it is important to note that 96 percent of the control patients received the TAXUS Express Stent, making the comparison almost entirely based on our first-generation technology. Of particular interest is the subgroup data on diabetics given the recent discussion in scientific journal
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
3. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
4. RenalGuard(R) Pilot Safety Clinical Trial Data to be Presented at ACC 2009
5. Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing
6. Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients
7. Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
8. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
9. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
10. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
11. Another LNA-based RNA Inhibitor Enters Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 InVivo Therapeutics ... MA is revolutionizing spinal cord injury (SCI) ... been shown to outperform in tissue regrowth in the ... scaffold.  Made from an FDA approved polymer, the scaffold ... it harmless to the human body. NVIV has recently ...
(Date:10/22/2014)... 22, 2014 WHEN: Wednesday, October 29, 2014 ... available at: http://bit.ly/1yStiU9 SPEAKERS: Visionary ... Visionary Innovation Research Group Senior Research Analyst ... materials, nanobots and flexible electronics are among ... our lives in the coming decades. These ...
(Date:10/22/2014)... -- Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in developing ... for cancer, is designed for injection into solid tumors ... focus is on melanoma, breast cancer and cancers of ... PV-10 as a therapy for metastatic melanoma, and of ... psoriasis. This summer, the Company signed ...
Breaking Medicine Technology:InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... 8 , - Glivec(R) (imatinib) ... KIT (CD117)-Positive Gastrointestinal Stromal Tumours,(GIST), who are at Significant Risk ... - Use of Glivec(R) After Surgery Significantly Reduces Risk ... After Surgery, 50% of patients Will Experience Their,Cancer Returning Within ...
... guidance regarding strategic transaction processSAN DIEGO, May 7 ... ANX ) today announced results from its bioequivalence ... determined to have comparable overall safety as Taxotere(R), ... groups in severe toxicities. However, pharmacokinetic equivalence, ...
Cached Medicine Technology:Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 2Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 3Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 4Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 5Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 6ADVENTRX Announces Results From ANX-514 Bioequivalence Study 2ADVENTRX Announces Results From ANX-514 Bioequivalence Study 3ADVENTRX Announces Results From ANX-514 Bioequivalence Study 4ADVENTRX Announces Results From ANX-514 Bioequivalence Study 5
(Date:10/25/2014)... Interrupting blood supply to an arm or a leg before ... surgery, according to a new study. "During heart ... heart to be able to operate on it. After some ... to produce energy because it doesn,t get oxygen. When we ... as an arm or a leg, the body prepares for ...
(Date:10/25/2014)... News) -- Not getting the right amount of sleep ... study suggests. Those who sleep less or more ... may be more prone to developing the chronic condition, ... study authors concluded that duration and quality of sleep ... inflammatory bowel diseases. "Both short and long durations ...
(Date:10/25/2014)... large influx of international aid is needed, and soon, ... of deaths from the widening Ebola crisis, a team ... specially designed mathematical model, the researchers looked at the ... populated county of hard-hit Liberia -- Montserrado County, home ... said that if international aid isn,t delivered to Liberia ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. ... developed that spot increased risks for certain cancers, one might ... screened. But a new study suggests that, at least ... found out their genes doubled their risk of colon cancer ... get screened. "It didn,t make any difference, not at ...
(Date:10/22/2014)... Pennsylvania (PRWEB) October 22, 2014 At ... and uncertainty among parents and athletes at all levels, ... working to change the current discussion where two powerful ... are evidence-based therapies that result in full recoveries every ... to one based in fact and research, UPMC and ...
Breaking Medicine News(10 mins):Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4
... S. Department of Health and Human Services (HHS) and ... launch National Infant Immunization Week (NIIW) with events// April ... are expected to participate in NIIW by sponsoring activities ... ,CDC and HHS will collaborate with state ...
... Brodie Campbell are still in shock and grief over the ... have reportedly brought in grief counselors to help students deal ... student at his school- Dr. Charles Best Secondary School in ... has now confirmed the reason of death as bacterial meningitis. ...
... losing its forests to over-exploitation, will get help in ... which signed up the// country as a member this ... Analysis (IIASA), Austria - a non-governmental research organization that ... the context of global change - has said it ...
... Institute of Medical Sciences (AIIMS) has developed artificial testis, ... genitals.// ,Doctors at the premier referral hospital ... such problems, achieving 100 percent success. ,"We ... patients with not a single case of rejection. From ...
... scam burst into the open in Paris, Dr. Brian ... three months by the// Californian state authorities. ... Area Laboratory Co-Operative that allegedly provided steroids to top ... five years' probation and ordered to undergo a psychiatric ...
... too serious a matter to be left in the hands of ... the care of labour department officials. At least such// seems to ... that agencies like the Occupational Safety and Health Administration ... than with the safety of the workers themselves. ...
Cached Medicine News:Health News:National Infant Immunization Week Urges Parents to Vaccinate On Time 2Health News:India to Protect Its Forests With the Aid of Austrian NGO 2Health News:Artificial Testis Developed by AIIMS a Boon to Suffering Patients 2Health News:US Psychiatrist Suspended from Practicing Medicine for Involvement in Doping Scam 2Health News:US Psychiatrist Suspended from Practicing Medicine for Involvement in Doping Scam 3Health News:Overseeing Agency Indifferent to Workplace Safety in US 2
View Mex-3 is designed for out-patient surgery, hospital rounds and house calls....
Headlight module is mounted on UltraLite Plus headband or sweatband....
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity....
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity....
Medicine Products: